> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fast Track Granted for Therabron Respiratory Drug
- URL: https://www.fdaweb.com/fast-track-granted-for-therabron-respiratory-drug/
- Published: 2016-04-28T12:00:00.000Z
- Updated: 2026-09-14T20:58:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135523

> FDA has granted Therabron Therapeutics fast track status for rhCC10 (recombinant human club cell 10 kDa protein) and its use in preventing chronic lung disease related to premature birth. The company says the investigational drug has potent anti-inflammatory properties for a variety of respiratory diseases. The drug is currently in a Phase 2 trial that is evaluating its use to prevent chronic lung disease in neonates. The trial, which is designed to enroll 88 preterm infants, is supported by a grant from the agency’s Office of Orphan Product Development.